At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed May 7, 2026 at 07:10 ET
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 by 10.4%. Collaboration revenue plunged to $0.9M from $20.6M a year ago as the Vertex research plan completed, but the company highlighted positive clinical data from ENTR-601-44 in Duchenne muscular dystrophy, showing favorable safety and early functional benefit.
- Net loss widened to $39.7M in Q1 2026 from $17.3M in Q1 2025 due to higher R&D costs and lower collaboration revenue.
- Collaboration revenue declined to $0.9M from $20.6M YoY as the Vertex VX-670 research plan substantially completed.
- Positive topline results from ELEVATE-44-201 Cohort 1: favorable safety, statistically significant improvement in Time to Rise velocity.
- Cash, cash equivalents and marketable securities of $254.9M, expected to fund operations into Q3 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access